To further evaluate the role of Nrf1 in this response, we used a panel of cell lines of different origin (NIH-3T3 murine fibroblasts, SH-SY5Y human neuroblastoma, HT22 mouse hippocampal neurons, and MDA-MB-231 human breast cancer) that are either control or Nrf1-deficient and assayed for changes in transcript levels of select ALP-related genes in response to treatment with the proteasome inhibitor carfilzomib (CFZ). Here, NRF1 is linked to breast carcinoma.